Glima Tablet 200 mg (Imatinib Mesylate)

Adult dose

For adult patients with chronic myeloid leukemia (CML), the recommended dose is 400mg once daily for Philadelphia chromosome-positive chronic-phase disease and 600mg once daily for accelerated-phase or blast-phase chronic myeloid leukemia. For adult patients with gastrointestinal stromal tumors (GIST), the recommended dose is 400mg daily. For myelodysplastic syndromes/myeloproliferative diseases, the dose is 400mg daily; for hypereosinophilic syndrome/chronic eosinophilic leukemia, the dose is 100mg daily, which may be increased to a maximum of 400mg; for recurrent or metastatic dermatofibrosarcoma protuberans, the recommended dose is 800mg daily (400mg twice daily). The 400mg or 600mg dose is taken once daily, and the 800mg dose is taken as 400mg twice daily. Take the prescribed dose with a meal and plenty of water.

Child dose

For pediatric patients with chronic myeloid leukemia (CML), a dose of 340mg/m2 per body surface area daily is recommended for Philadelphia chromosome-positive chronic-phase, accelerated-phase, and blast-phase disease. The total daily dose should not exceed 600mg and may be given once daily or divided into 2 doses, in the morning and evening. In pediatric patients, the medication may be taken once daily or, alternatively, the daily dose may be divided into 2 doses taken in the morning and evening.

This medication should not be used in patients who have an allergic reaction to this medication or its other components. Women who are pregnant or may become pregnant should not take this medication. Breastfeeding women should also not take this medication. Patients with impaired liver or kidney function should exercise extreme caution when using this medication. Patients with a history of heart disease, heart failure, or kidney failure need to carefully monitor their heart and kidney status while taking this medication. Due to the potential risk of cardiac issues in patients with hypereosinophilia syndrome, evaluation by a cardiologist before administration may be necessary. Patients taking levothyroxine after thyroid surgery should have regular thyroid function tests. Growth retardation may occur in pediatric patients, so their growth should be closely monitored. Serious side effects known as tumor lysis syndrome can occur while taking this medication, thus hydration before administration and management of uric acid levels should be ensured. Patients who are carriers of Hepatitis B virus should undergo virus testing before taking this medication and consult specialists as needed, while also closely monitoring liver condition during treatment. Various side effects such as neutropenia, thrombocytopenia, anemia, headache, dyspepsia, edema, nausea, vomiting, myalgia, diarrhea, rash, fatigue, abdominal pain, gastrointestinal and tumor-related bleeding, gastrointestinal obstruction, perforation, ulcer, hepatotoxicity, acute renal failure, hypophosphatemia, tumor lysis syndrome, and growth delay may occur during the use of this medication. If side effects are severe, dosage adjustments or discontinuation may be necessary, thus any unusual symptoms should be reported to medical staff immediately.

Neutropenia, thrombocytopenia, anemia, headache, dyspepsia, edema, weight gain, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, abdominal pain, bone marrow suppression, gastrointestinal and tumor-related bleeding, gastrointestinal obstruction, perforation, ulceration, hepatotoxicity, acute renal failure, hypophosphatemia, severe respiratory adverse reactions, tumor lysis syndrome, growth retardation in children, hypothyroidism, growth delay, cardiogenic shock, left ventricular dysfunction, reactivation of hepatitis B

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it should be kept at room temperature between 1 degree and 30 degrees Celsius to maintain its effectiveness.

Appearance

Dark yellow to brown round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)